KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Receivables - Other (2017 - 2024)

Neogenomics filings provide 8 years of Receivables - Other readings, the most recent being $100000.0 for Q4 2024.

  • On a quarterly basis, Receivables - Other rose 170.27% to $100000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $100000.0, a 170.27% increase, with the full-year FY2024 number at $100000.0, up 170.27% from a year prior.
  • Receivables - Other hit $100000.0 in Q4 2024 for Neogenomics, down from $236000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $2.9 million in Q3 2022 to a low of $37000.0 in Q4 2023.
  • Median Receivables - Other over the past 5 years was $1.7 million (2020), compared with a mean of $1.5 million.
  • Biggest five-year swings in Receivables - Other: soared 590.62% in 2020 and later crashed 98.05% in 2023.
  • Neogenomics' Receivables - Other stood at $1.9 million in 2020, then increased by 2.12% to $2.0 million in 2021, then fell by 3.85% to $1.9 million in 2022, then crashed by 98.05% to $37000.0 in 2023, then soared by 170.27% to $100000.0 in 2024.
  • The last three reported values for Receivables - Other were $100000.0 (Q4 2024), $236000.0 (Q1 2024), and $37000.0 (Q4 2023) per Business Quant data.